Clobazam
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Clobazam and local guidelines before prescribing.
Mechanism
Benzodiazepine enhancing GABA-A receptor activity (1,5-benzodiazepine).
Uses
Adjunct in epilepsy, Lennox-Gastaut, intermittent seizure prophylaxis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Drowsiness, dizziness, tolerance, withdrawal seizures, behavioural change.
Interactions
Additive sedation with alcohol and opioids; enzyme inducers lower levels; stiripentol and cannabidiol raise active metabolite.
Contraindications and cautions
Respiratory depression, severe liver impairment, myasthenia gravis
Monitoring
Sedation, tolerance
Pregnancy and breastfeeding
Specialist advice
Renal and hepatic impairment
Reduce dose in renal and hepatic impairment
Overdose and reversal
Flumazenil rarely; supportive
Special advice
Avoid abrupt withdrawal; tolerance may develop; avoid driving until effects known.
More from the textbook: uses, cautions and other points
- Brand consistency (MHRA categories) - keep patients on the same manufacturer for category 1 drugs ( phenytoin, carbamazepine, phenobarbital, primidone ); use clinical judgement for category 2 (valproate, lamotrigine, topiramate, oxcarbazepine, clobazam, others).
Neurology: Anatomy, Physiology and Pharmacology - Clobazam and clonazepam (benzodiazepines) - add-on and short-term "cover" (e.g. around periods - catamenial epilepsy); tolerance, sedation, dependence.
Neurology: Anatomy, Physiology and Pharmacology - Catamenial epilepsy (around periods) - specialist options include intermittent clobazam.
Neurology: Epilepsy - Clobazam | Short-term add-on (e.g. catamenial, clusters); tolerance.
Neurology: Epilepsy - Dravet syndrome | SCN1A mutation; prolonged febrile and afebrile seizures from the first year, then developmental slowing. Avoid sodium channel blockers (carbamazepine, lamotrigine, phenytoin). Valproate, clobazam, stiripentol, fenfluramine, cannabidiol.
Paediatrics: Neurology, bones and joints in children
Where it is discussed in the book
- Neurology: Anatomy, Physiology and Pharmacology (2 mentions)
- Neurology: Epilepsy (2 mentions)
- Paediatrics: Neurology, bones and joints in children (1 mention)
- Integrated paediatrics chapter (1 mention)